In TMZ-resistant xenograft animal models, the combination of PARP inhibitors with TMZ decreased glioma development, suggesting the possibility of a synthetic lethal strategy for overcoming ATRX-mediated TMZ resistance in gliomas. This evidence concerns the gene PARP1 and central nervous system cancer.